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Introduction: Coronavirus disease-2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), is causing dramatic morbidity and
mortality worldwide. The Red Blood Cell Distribution Width (RDW) has been strongly
associated with increased morbidity and mortality in multiple diseases.
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Objective: To assess if elevated RDW is associated with unfavorable outcomes in
hospitalized COVID-19.
Methods: We retrospectively studied clinical outcomes of hospitalized COVID-19
patients for their RDW values. In-hospital mortality was defined as primary outcome,
while septic shock, need for mechanical ventilation, and length of stay (LOS) were
secondary outcomes.
Results: A total of 294 COVID-19 patients were finally studied. Overall prevalence
of increased RDW was 49.7% (146/294). RDW was associated with increased risk of
in-hospital mortality (aOR, 4.6; 95%CI, 1.5-14.6) and septic shock (aOR, 4.6; 95%CI,
1.4-15.1) after adjusting for anemia, ferritin, lactate, and absolute lymphocyte count.
The association remained unchanged even after adjusting for other clinical confounders
such as age, sex, body mass index, coronary artery disease, hypertension, diabetes
mellitus, and chronic obstructive pulmonary disease. No association was found instead
with mechanical ventilation and median LOS.
Conclusion: Elevated RDW in hospitalized COVID-19 patients is associated with a
significantly increased risk of mortality and septic shock.
Keywords: COVID-19, Red cell distribution width (RDW), SARS-CoV-2, septic shock, mortality, length of stay
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INTRODUCTION
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome corona virus-2 (SARS-CoV-2), has started as a cluster of pneumonia-like illness in
Wuhan, China, and has now spread all around the world (1). During the initial outbreak of
COVID-19, respiratory involvement was the primary cause of morbidity and mortality. As of June
18, 2020, COVID-19 had infected over 9 million people, causing 450,000 deaths, and numbers
continue to rise (2). As the number of patients increased, other organ system involvement
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were increasingly recognized (3–8). The US Center for Disease
Control and Prevention (CDC) emphasizes that patients with
preexisting conditions such as advanced age (65 years or older)
or pathologies like cardiovascular disease, diabetes, cancer,
hypertension, chronic obstructive pulmonary disease (COPD)
are at higher risk of COVID-19-associated morbidity and
mortality (9).
It is now unquestionable that early identification and prompt
management of COVID-19 could prevent or delay the onset
of life-threatening complications. In addition to preexisting
conditions, the use of prognostic laboratory biomarkers may be
of great clinical significance for identifying patients at higher risk
of worse progression. Similar to other viral illnesses, COVID-19
is associated with leukopenia, lymphopenia, and elevated values
of many traditional inflammatory biomarkers (10, 11).
RDW is an inexpensive measure of erythrocyte size variation,
and it can be used in the differential diagnosis of hematological
disturbances such as iron deficiency anemia and bone marrow
dysfunction (12). This parameter is calculated as the standard
deviation (SD) of red blood cell (RBC) volume, divided by the
mean corpuscular volume (MCV), thus providing a quantitative
estimation of anisocytosis. Alteration of erythropoiesis can result
in extensive heterogeneity of RBC size, which can provide
indirect evidence of existing and ongoing pathological changes.
In inflammatory states, the turnover of the RBC is decreased,
with a simultaneous increase of inflammatory cell turnover
(e.g., leukocytes and platelets) in the attempt to counteract the
infection (13). Due to these changes, RDW is usually elevated
in conditions such as advanced age, diabetes, cardiovascular

diseases, gastrointestinal disorders, infections, and a vast array of
infections and inflammatory states (14–18).
As the pathogenesis of COVID-19 involves both infection
and inflammation, the RDW measured at hospital admission
could potentially be considered a reliable index for identifying
patients at higher risk of an unfavorable outcome (19).
Therefore, this study aimed to explore whether RDW value
upon admission may predict clinical progression in patients
hospitalized for COVID-19.

METHODS
This retrospective descriptive study was carried out from a single
tertiary care academic Medical Center in New York City. The
Institutional Review Board approved the study.
The initial study population consisted of all consecutive adult
patients admitted to the hospital with confirmed SARS-CoV2 infection from January 20, 2020, to April 25, 2020. The
study cohort was stratified into two groups according to the
RDW value (elevated, cases; normal, controls). The RDW is
measured using the Beckman Coulter analyzer. Elevated RDW
was defined as a value > 14.6%, which is the upper limit of the
healthy adult reference interval in the local institution. Inclusion
criteria included all adult patients (age > 18 years) hospitalized
for COVID-19, thus testing positive for SARS-CoV-2 on the
nasopharyngeal swab, according to current guidelines (20).
Exclusion criteria were- individuals who were not hospitalized
or treated on an ambulatory basis, age < 18 years, pregnancy,
non-availability of nasopharyngeal testing, lack of clinical or

FIGURE 1 | Study flowchart. COVID-19, Coronavirus Disease 2019; RDW, Red blood cell distribution width.
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TABLE 1 | Baseline demographics of the study populatione .
Characteristic

Age, median (IQR), years
Age > 60 years
Female gender

RDW elevated

RDW normal

group

control group

N = 146

N = 148

66.1 (57, 76.3)

63 (52, 73)

105 (71.9)

TABLE 2 | Laboratory data in hospitalized COVID-19 patients according to their
red blood cell distribution width (RDW) value.
P-value
Characteristic

85 (58.2)

49 (33.1)

<0.001

91 (61.5)

0.06

33/44 (75)

43/47 (91.5)

0.048

Elevated
D-dimer

28/34 (82.4)

30/35 (85.7)

0.75

56 (37.8)

0.02
0.95

3 (2.1)

6 (2.1)

0.50

African American

109 (74.7)

98 (66.2)

0.13

Hispanic

17 (11.6)

22 (14.9)

0.49

2 (1.4)

8 (5.4)

15 (10.3)

14 (9.5)

Race (%)

Unknown

P-value

Anemia

29.1 (25.9, 33.9)

Asian

N = 148

Elevated
Ferritin

76 (52.1)

White

RDW normal group

N = 146
0.02

29.1 (25.6, 34.9)

BMI, median (IQR), kg/m2

RDW elevated group

Leukocytosis

39 (26.7)

32 (21.6)

0.34

Lymphopenia

88 (60.3)

81 (54.7)

0.35

Thrombocytopenia

24 (16.4)

37 (25)

0.08

62 (42.5)

48 (32.9)

0.17

0.10

Elevated
creatinine

0.85

Hypoalbuminemia

43 (29.5)

37 (25.2)

0.43

Elevated
creatinine
phosphokinase

9/69 (13)

11/86 (12.8)

1.00

Elevated
lactate

57/118 (48.3)

40/121 (33.1)

0.018

Elevated
LDH

124/124 (100)

128/129 (99.2)

1

Elevated
CRP

67 /117 (57.3)

59/121 (48.8)

0.19

Comorbidities (%)
Hypertension

116 (79.5)

93 (62.8)

0.002

Dyslipidemia

49 (33.6)

48 (32.4)

0.90

CAD

29 (19.9)

16 (10.8)

0.04

DM

72 (49.3)

60 (40.5)

0.16

Cancer

14 (9.6)

6 (4.1)

0.07

COPD

19 (13)

8 (5.4)

0.03

Asthma

23 (15.8)

21 (14.2)

0.75

Immunocompromised status (%)

15 (10.3)

9 (6.1)

0.21

74 (50.3)

0.35

17 (12.1)

15 (10.3)

0.71

Elevated
AST

65 (44.8)

Smoker (%)

30 (20.4)

0.22

29 (26.4)

0.06

Elevated
ALT

21 (14.6)

54 (37)
21 (14.7)

24 (16.9)

0.63

Elevated
bilirubin

19 (13)

15 (10.2)

0.47

25 (17.2)

16 (10.9)

0.13

Medications (%)
ACEI/ARB
NSAID
Aspirin

48 (33.6)

40 (28.2)

0.37

Statin

63 (44.1)

51 (35.9)

0.18

H2B

9 (6.2)

8 (5.4)

0.81

PPI

28 (19.2)

18 (12.2)

0.11

84 (57.5)

93 (62.8)

0.40

Elevated
alkaline
phosphatase

LDH, Lactate Dehydrogenase; CRP, C-reactive protein; AST, Aspartate aminotransferase;
ALT, Alanine aminotransferase.

Symptoms (%)
Cough
Fever

84 (57.5)

92 (62.2)

0.48

Dyspnea

104 (71.2)

98 (66.2)

0.38

Fatigue

51 (34.9)

60 (40.5)

0.34

Myalgia

38 (26)

40 (27)

0.89

GI symptom

20 (13.7)

33 (22.3)

0.07

Pneumonia (%)

137 (93.8)

130 (87.8)

0.11

TABLE 3 | Outcomes data on hospitalized COVID-19 patients according to their
red blood cell distribution width (RDW) value.
Characteristic

BMI, Body mass Index; CAD, Coronary artery disease; DM, Diabetes Mellitus; COPD,
Chronic Obstructive Pulmonary disease; ACEI, Angiotensin-converting enzyme inhibitors;
ARB, Angiotensin II receptor blockers; NSAID, Non-steroidal anti-inflammatory drugs;
H2B, H2 blockers; PPI, Proton Pump Inhibitors; GI, gastrointestinal.
e Non-parametric test (Mann-Whitney test) used for non-normal distributed continuous
variables, chi-square analysis was used to compare categorical variables.

RDW normal group

N = 146

N = 148

P-value

In-hospital mortality

34 (23.3)

22 (15.1)

0.10

Shock

55 (37.7)

38 (25.7)

0.03

Mechanical ventilation

29 (19.9)

20 (13.5)

0.19

Statistical analysis was performed using IBM SPSS software
version 26 (SPSS Inc, Armonk, NY). Descriptive summary
statistics are shown as median with interquartile range (IQR) for
continuous variables since most were not normally distributed,
and frequencies with percentages for categorical variables.
Categorical and continuous variables were tested for statistical
significance using chi-square tests and t-tests, respectively.
We performed two models of multivariable logistic regression
analyses. In the first model, we included other laboratory
variables such as anemia, elevated ferritin, elevated lactate,
and absolute lymphocyte count at admission. In the second

laboratory information on disposition and/or mortality data
anemia was defined as a hemoglobin value < 130 g/L in males
and <120 g/L in females, respectively.
Information on patient demographics, presenting symptoms,
comorbidities, home medications, and initial laboratory tests
were obtained at hospital admission. In-hospital mortality
from any cause was defined as the primary outcome in this
study, whilst septic shock, need for mechanical ventilation,
and in-hospital length of stay (LOS) were secondary outcomes.

Frontiers in Medicine | www.frontiersin.org
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TABLE 4 | Multivariable Logistic Regression Analysis of elevated red blood cell
distribution width (RDW) value.
Variables

Adjusted odds ratio (aOR)

P-value

with 95% confidence interval (CI)
Model 1e
Death

4.6 (1.5-14.6)

0.009

Septic shock

4.6 (1.4-15.1)

0.011

Mechanical ventilation

2.2 (0.7-6.8)

0.183

Model 2£
Death

5.5 (1.3-23.1)

0.019

Septic shock

5.5 (1.4-21.3)

0.015

Mechanical ventilation

1.4 (0.4-4.9)

0.596

e Model 1, Adjusted for Anemia, Elevated Ferritin, elevated Lactate and Absolute
lymphocyte count.
£ Model 2, Adjusted for Age, Gender, Body mass index, coronary artery disease,
Hypertension, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, Anemia,
elevated Ferritin, elevated Lactate and Absolute lymphocyte count.

model, we also included other clinically relevant variables such
as age, sex, body mass index (BMI), coronary artery disease
(CAD), hypertension, diabetes mellitus, and chronic obstructive
pulmonary disease (COPD) in addition to the laboratory
variables mentioned above. The results of the regression models
were provided as adjusted odds ratio (aOR) and its 95%
confidence interval (CI). The receiver operating characteristic
(ROC) curve was used for exploring the discriminant power of
the model.

RESULTS
The initial study population consisted of 300 patients hospitalized
for COVID-19, six of whom ought to be excluded due to
undefined results of SARS CoV-2 testing and lack of key outcome
variables. Therefore, a final number of 294 patients composed
the final study population (Figure 1). The prevalence of elevated
RDW values was found to be 49.7% (146/294).

FIGURE 2 | (A) Receiver Operator Curve (ROC) of red blood cell distribution
width (RDW) values in coronavirus disease 2019 (COVID-19) patients for
predicting mortality. (B) Receiver Operator Curve (ROC) of red blood cell
distribution width (RDW) values in coronavirus disease 2019 (COVID-19)
patients for predicting septic shock.

Baseline Demographics
Outcomes

Baseline demographic data and comorbidities in patients with or
without elevated RDW value are summarized in Table 1. Patients
with elevated RDW were older with female predominance.
Patients with elevated RDW value had also a higher prevalence
of hypertension, CAD and COPD.

The outcomes of the study are shown in Table 3. The COVID19 patients with elevated RDW values had a higher frequency
of in-hospital mortality compared to those with normal RDW
values, but the difference was not statistically significant (23.3
vs. 15.1%, P = 0.1). However, after adjusting for lactate, ferritin,
absolute lymphocyte count, and anemia, elevated RDW was
found to be significantly associated with a higher risk of inhospital mortality (aOR 4.6, 95% CI 1.5-14.6; p = 0.009). The
incidence of shock was also higher in the elevated RDW group
(37.7 vs. 25.7%; p = 0.03) compared to patients with normal
RDW values. Elevated RDW was associated with a 4.6-fold
higher odds of shock (aOR 4.6, 95% CI 1.4-15.1; p = 0.01)
after adjusting for confounders (Table 4). No association with
RDW value was found for the need for mechanical ventilation or
in-hospital (LOS).

Laboratory Data
Laboratory data at the time of admission in patients with or
without elevated RDW value are summarized in Table 2. The
prevalence of anemia was higher in patients with increased RDW
value than in those without elevated RDW. Elevated lactate values
were also more frequent in patients with increased RDW value
than those without elevated RDW. The rate of abnormal values
of lymphocyte count, platelet count, D-dimer, C reactive protein
(CRP), aminotransferases, bilirubin, and alkaline phosphatase
did not differ between the two cohorts of patients.

Frontiers in Medicine | www.frontiersin.org
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Analysis by ROC

balance (26). Our study showed an increased lactate level in
patients with RDW values above the normal threshold, thus
correlating with the increased incidence of shock and mortality.
The increased RDW was found to be independently associated
with a higher incidence of shock and mortality after adjusting for
all the confounding variables. Whether higher RDW can predict
rates of altered hemodynamics and early features of shock in
these patients is unclear and remains to be studied.
RDW has been previously studied in patients with severe
sepsis and septic shock. Wang et al. noted that higher levels of
RDW were an independent predictor of in-hospital mortality in
elderly patients with sepsis and could potentially be used as a
reliable biomarker for predicting clinical outcomes (29). RDW
has also been used as a prognostic biomarker for predicting 28day mortality in patients with severe sepsis and septic shock
(30, 31). Recently, Foy et al. showed that elevated RDW at
diagnosis and its increase during hospitalization were associated
with an increased risk of mortality in patients with COVID19 (32), thus supporting our evidence. Nonetheless, the need
for mechanical ventilation and the LOS did not differ between
cases and controls, and this probably attributable to adequate
resuscitative efforts enabled by an early risk stratification. In
addition, other markers of inflammation such as D-dimer,
leukocytosis, C-reactive protein (CRP) did not differ significantly
according to the RDW threshold, thus paving the way to further
studies aimed at precisely establishing the role of anisocytosis in
the pathogenesis of COVID-19.

The ROC area under the curve (AUC) was found to be 0.85
and 0.77 for predicting mortality (Figure 2A) and septic shock
(Figure 2B), respectively. It had a sensitivity of 70% in predicting
both mortality and septic shock.

DISCUSSION
Based on our study, nearly half (49.7%) of patients hospitalized
for COVID-19 were found to have elevated RDW values
at presentation. Patients with increased RDW, thereby more
significant anisocytosis, had an increased risk of in-hospital
mortality and septic shock compared to those with normal
values. These findings remained significant after adjusting for
potential confounders. On the other hand, we failed to find
a significant association between RDW and the need for
mechanical ventilation and LOS.
RDW increases with age, especially among females (21). This
is probably due to decreased RBC deformability developing in
parallel with aging. Similarly, RDW is identified as an important
risk factor in the diagnosis and prognosis of patients with
cardiovascular disease (CVD) (12). While the precise mechanism
remains speculative, a combination of RDW and validated
cardiac markers can help to identify patients with CVD earlier,
thus allowing them to establish more appropriate and targeted
management. Our study showed a similar prevalence of higher
RDW with older age and female sex among cases compared to
controls. Furthermore, the presence of hypertension and CAD
was higher in patients with increased RDW (22, 23), and this
is in keeping with earlier studies and is also representative of
populations with preexisting health conditions (13, 14, 21).
The precise mechanism by which RDW elevation develops
in COVID-19 patients is unclear. Prior studies showed an
association of elevated RDW with increased inflammatory
markers, oxidative stress with impaired iron metabolism, which
would ultimately promote RBC apoptosis, and variance in their
morphology (13, 24, 25). COVID-19 patients are known to have a
significant inflammatory response, which can lead to multiorgan
failure. It is possible that the increased RDW in COVID-19
patients is due to this inflammatory response (26). It is wellknown that SARS-CoV-2 enters human cells via angiotensinconverting enzyme 2 (ACE-2) (27). The expression of ACE2 varies significantly among organs and tissues, which would
explain the different degrees of the vulnerability of host cells to
viral entry and cytopathic effects (28). The use of medications
such as ACEI/ARB in our study was higher in cases compared
to controls (37 vs. 26.4%; p = 0.06) but did not reach statistical
significance. It can, at least in part, explain the gastrointestinal
manifestations such as nausea, vomiting, diarrhea and abnormal
liver tests in patients with enhanced RDW values.
Higher admission RDW may reflect the presence of ongoing
chronic and severe inflammation. Some patients with COVID19 develop a cytokine storm syndrome, characterized by
overproduction of early response pro-inflammatory cytokines
such as tumor necrosis factor, interleukin [IL]-6, and IL1β (26). It can lead to increased vascular permeability,
hyper-inflammation, and loss of procoagulant-anticoagulant
Frontiers in Medicine | www.frontiersin.org

CONCLUSION
Elevated RDW is a common finding in patients hospitalized for
COVID-19. The preliminary findings of this study show that
elevated RDW at admission is present in almost half of patients
and independently predicts shock and mortality but not LOS or
need for mechanical ventilation.
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